193 related articles for article (PubMed ID: 36360213)
1. The Complex Dynamic of Phase I Drug Metabolism in the Early Stages of Doxorubicin Resistance in Breast Cancer Cells.
Barata IS; Gomes BC; Rodrigues AS; Rueff J; Kranendonk M; Esteves F
Genes (Basel); 2022 Oct; 13(11):. PubMed ID: 36360213
[TBL] [Abstract][Full Text] [Related]
2. Down-Regulation of CYP3A4 by the K
Ohya S; Kajikuri J; Kito H; Matsui M
Int J Mol Sci; 2023 Oct; 24(21):. PubMed ID: 37958656
[TBL] [Abstract][Full Text] [Related]
3. Targeting P-glycoprotein function, p53 and energy metabolism: Combination of metformin and 2-deoxyglucose reverses the multidrug resistance of MCF-7/Dox cells to doxorubicin.
Xue C; Wang C; Sun Y; Meng Q; Liu Z; Huo X; Sun P; Sun H; Ma X; Ma X; Peng J; Liu K
Oncotarget; 2017 Jan; 8(5):8622-8632. PubMed ID: 28052008
[TBL] [Abstract][Full Text] [Related]
4. LINC00160 mediated paclitaxel-And doxorubicin-resistance in breast cancer cells by regulating TFF3 via transcription factor C/EBPβ.
Wu H; Gu J; Zhou D; Cheng W; Wang Y; Wang Q; Wang X
J Cell Mol Med; 2020 Aug; 24(15):8589-8602. PubMed ID: 32652877
[TBL] [Abstract][Full Text] [Related]
5. Involvement of Cox-2 in the metastatic potential of chemotherapy-resistant breast cancer cells.
Kang JH; Song KH; Jeong KC; Kim S; Choi C; Lee CH; Oh SH
BMC Cancer; 2011 Aug; 11():334. PubMed ID: 21813027
[TBL] [Abstract][Full Text] [Related]
6. A P-glycoprotein- and MRP1-independent doxorubicin-resistant variant of the MCF-7 breast cancer cell line with defects in caspase-6, -7, -8, -9 and -10 activation pathways.
Park SJ; Wu CH; Safa AR
Anticancer Res; 2004; 24(1):123-31. PubMed ID: 15015586
[TBL] [Abstract][Full Text] [Related]
7. Overexpression of RSK4 reverses doxorubicin resistance in human breast cancer cells via PI3K/AKT signalling pathway.
Mei Y; Liao X; Zhu L; Yang H
J Biochem; 2020 Jun; 167(6):603-611. PubMed ID: 31960922
[TBL] [Abstract][Full Text] [Related]
8. Schisandrin A reverses doxorubicin-resistant human breast cancer cell line by the inhibition of P65 and Stat3 phosphorylation.
Zhang ZL; Jiang QC; Wang SR
Breast Cancer; 2018 Mar; 25(2):233-242. PubMed ID: 29181822
[TBL] [Abstract][Full Text] [Related]
9. Comparative sphingolipidomic analysis reveals significant differences between doxorubicin-sensitive and -resistance MCF-7 cells.
Shammout ODA; Ashmawy NS; Shakartalla SB; Altaie AM; Semreen MH; Omar HA; Soliman SSM
PLoS One; 2021; 16(10):e0258363. PubMed ID: 34637456
[TBL] [Abstract][Full Text] [Related]
10. Effect of β-elemene on the kinetics of intracellular transport of d-luciferin potassium salt (ABC substrate) in doxorubicin-resistant breast cancer cells and the associated molecular mechanism.
Tang CY; Zhu LX; Yu JD; Chen Z; Gu MC; Mu CF; Liu Q; Xiong Y
Eur J Pharm Sci; 2018 Jul; 120():20-29. PubMed ID: 29704644
[TBL] [Abstract][Full Text] [Related]
11. Effect of resveratrol on doxorubicin resistance in breast neoplasm cells by modulating PI3K/Akt signaling pathway.
Chen JM; Bai JY; Yang KX
IUBMB Life; 2018 Jun; 70(6):491-500. PubMed ID: 29637742
[TBL] [Abstract][Full Text] [Related]
12. The carotenoid fucoxanthin can sensitize multidrug resistant cancer cells to doxorubicin via induction of apoptosis, inhibition of multidrug resistance proteins and metabolic enzymes.
Eid SY; Althubiti MA; Abdallah ME; Wink M; El-Readi MZ
Phytomedicine; 2020 Oct; 77():153280. PubMed ID: 32712543
[TBL] [Abstract][Full Text] [Related]
13. Small-molecule synthetic compound norcantharidin reverses multi-drug resistance by regulating Sonic hedgehog signaling in human breast cancer cells.
Chen YJ; Kuo CD; Chen SH; Chen WJ; Huang WC; Chao KS; Liao HF
PLoS One; 2012; 7(5):e37006. PubMed ID: 22615870
[TBL] [Abstract][Full Text] [Related]
14. 15-LOX-1 has diverse roles in the resensitization of resistant cancer cell lines to doxorubicin.
Kazan HH; Urfali-Mamatoglu C; Yalcin GD; Bulut O; Sezer A; Banerjee S; Gunduz U
J Cell Physiol; 2020 May; 235(5):4965-4978. PubMed ID: 31663148
[TBL] [Abstract][Full Text] [Related]
15. Pluronic P123 modified nano micelles loaded with doxorubicin enhanced tumor-suppressing effect on drug-resistant breast cancer cells.
Zhang X; Chen W; Bai J; Jin L; Kang X; Zhang H; Wang Z
Aging (Albany NY); 2020 May; 12(9):8289-8300. PubMed ID: 32396524
[TBL] [Abstract][Full Text] [Related]
16. Drug resistance associates with activation of Nrf2 in MCF-7/DOX cells, and wogonin reverses it by down-regulating Nrf2-mediated cellular defense response.
Zhong Y; Zhang F; Sun Z; Zhou W; Li ZY; You QD; Guo QL; Hu R
Mol Carcinog; 2013 Oct; 52(10):824-34. PubMed ID: 22593043
[TBL] [Abstract][Full Text] [Related]
17. Systematic expression analysis of genes related to multidrug-resistance in isogenic docetaxel- and adriamycin-resistant breast cancer cell lines.
Li WJ; Zhong SL; Wu YJ; Xu WD; Xu JJ; Tang JH; Zhao JH
Mol Biol Rep; 2013 Nov; 40(11):6143-50. PubMed ID: 24078162
[TBL] [Abstract][Full Text] [Related]
18. Human pharmacokinetic characterization and in vitro study of the interaction between doxorubicin and paclitaxel in patients with breast cancer.
Gianni L; Viganò L; Locatelli A; Capri G; Giani A; Tarenzi E; Bonadonna G
J Clin Oncol; 1997 May; 15(5):1906-15. PubMed ID: 9164201
[TBL] [Abstract][Full Text] [Related]
19. Effects of monensin liposomes on the cytotoxicity, apoptosis and expression of multidrug resistance genes in doxorubicin-resistant human breast tumour (MCF-7/dox) cell-line.
Shaik MS; Chatterjee A; Singh M
J Pharm Pharmacol; 2004 Jul; 56(7):899-907. PubMed ID: 15233869
[TBL] [Abstract][Full Text] [Related]
20. Expression of Bax, Bad and Bcl-2 proteins under x-radiation effect towards human breast carcinoma MCF-7 cells and their doxorubicin-resistant derivatives.
Chorna IV; Datsyuk LO; Stoika RS
Exp Oncol; 2005 Sep; 27(3):196-201. PubMed ID: 16244580
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
